BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33960497)

  • 1. Observation policy for sentinel node metastasis of melanoma: Comparative study with completion lymph node dissection in Japanese patients.
    Matsui Y; Sasaki J; Takatsuka S; Takenouchi T
    J Dermatol; 2021 Aug; 48(8):1221-1228. PubMed ID: 33960497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.
    Faries MB; Thompson JF; Cochran AJ; Andtbacka RH; Mozzillo N; Zager JS; Jahkola T; Bowles TL; Testori A; Beitsch PD; Hoekstra HJ; Moncrieff M; Ingvar C; Wouters MWJM; Sabel MS; Levine EA; Agnese D; Henderson M; Dummer R; Rossi CR; Neves RI; Trocha SD; Wright F; Byrd DR; Matter M; Hsueh E; MacKenzie-Ross A; Johnson DB; Terheyden P; Berger AC; Huston TL; Wayne JD; Smithers BM; Neuman HB; Schneebaum S; Gershenwald JE; Ariyan CE; Desai DC; Jacobs L; McMasters KM; Gesierich A; Hersey P; Bines SD; Kane JM; Barth RJ; McKinnon G; Farma JM; Schultz E; Vidal-Sicart S; Hoefer RA; Lewis JM; Scheri R; Kelley MC; Nieweg OE; Noyes RD; Hoon DSB; Wang HJ; Elashoff DA; Elashoff RM
    N Engl J Med; 2017 Jun; 376(23):2211-2222. PubMed ID: 28591523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial.
    Leiter U; Stadler R; Mauch C; Hohenberger W; Brockmeyer N; Berking C; Sunderkötter C; Kaatz M; Schulte KW; Lehmann P; Vogt T; Ulrich J; Herbst R; Gehring W; Simon JC; Keim U; Martus P; Garbe C;
    Lancet Oncol; 2016 Jun; 17(6):757-767. PubMed ID: 27161539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence and implementation gaps in management of sentinel node-positive melanoma in the United States.
    Broman KK; Richman J; Bhatia S
    Surgery; 2022 Jul; 172(1):226-233. PubMed ID: 35120732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the changes in the completion lymph node dissection criteria and approval of adjuvant therapies on the real-world outcomes of Japanese stage III melanoma patients.
    Ogata D; Tanese K; Nakamura Y; Otsuka M; Namikawa K; Funakoshi T; Yoshikawa S; Tsutsui K; Nakama K; Jinnai S; Kiyohara Y; Takahashi A; Yamazaki N
    Int J Clin Oncol; 2021 Dec; 26(12):2338-2346. PubMed ID: 34545533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete lymph node dissection or observation in melanoma patients with multiple positive sentinel lymph nodes: A single-center retrospective analysis.
    Persa OD; Knuever J; Mauch C; Schlaak M
    J Dermatol; 2018 Oct; 45(10):1191-1194. PubMed ID: 30095864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Completion lymph node dissection in patients with sentinel lymph node positive cutaneous head and neck melanoma.
    Huang K; Misra S; Lemini R; Chen Y; Speicher LL; Dawson NL; Tolaymat LM; Bagaria SP; Gabriel EM
    J Surg Oncol; 2020 Nov; 122(6):1057-1065. PubMed ID: 32654173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary excision margins, sentinel lymph node biopsy, and completion lymph node dissection in cutaneous melanoma: a clinical practice guideline.
    Wright FC; Souter LH; Kellett S; Easson A; Murray C; Toye J; McCready D; Nessim C; Ghazarian D; Hong NJL; Johnson S; Goldstein DP; Petrella T;
    Curr Oncol; 2019 Aug; 26(4):e541-e550. PubMed ID: 31548823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Stage III melanoma: Sentinel node biopsy, completion lymph node dissection and prospects of adjuvant therapy. A French national survey on current and envisaged practices].
    Orion C; Dinulescu M; Dalac-Rat S; Giacchero D; Jouary T; Lebbé C; Leccia MT; Maubec E; Meyer N; Mortier L; Dupuy A;
    Ann Dermatol Venereol; 2020 Jan; 147(1):9-17. PubMed ID: 31761496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surveillance of Sentinel Node-Positive Melanoma Patients Who Receive Adjuvant Therapy Without Undergoing Completion Lymph Node Dissection.
    Broman KK; Bettampadi D; Pérez-Morales J; Sun J; Kirichenko D; Carr MJ; Eroglu Z; Tarhini AA; Khushalani N; Schabath MB; Sarnaik A; Sondak VK; Zager JS
    Ann Surg Oncol; 2021 Nov; 28(12):6978-6985. PubMed ID: 34363118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Completion Lymph Node Dissection on Patients with Positive Sentinel Lymph Node Biopsy in Melanoma.
    Lee DY; Lau BJ; Huynh KT; Flaherty DC; Lee JH; Stern SL; O'Day SJ; Foshag LJ; Faries MB
    J Am Coll Surg; 2016 Jul; 223(1):9-18. PubMed ID: 27236435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nodal and systemic recurrence following observation of a positive sentinel lymph node in melanoma.
    Bartlett EK; Lee AY; Spanheimer PM; Bello DM; Brady MS; Ariyan CE; Coit DG
    Br J Surg; 2020 Oct; 107(11):1480-1488. PubMed ID: 32484242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant Therapy is Effective for Melanoma Patients with a Positive Sentinel Lymph Node Biopsy Who Forego Completion Lymphadenectomy.
    Farrow NE; Raman V; Williams TP; Nguyen KY; Tyler DS; Beasley GM
    Ann Surg Oncol; 2020 Dec; 27(13):5121-5125. PubMed ID: 32314157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant Therapy for Stage III Melanoma Without Immediate Completion Lymph Node Dissection.
    Torphy RJ; Friedman C; Ho F; Leonard LD; Thieu D; Lewis KD; Medina TM; Robinson WA; Gonzalez RC; Stewart CL; Kounalakis N; McCarter MD; Gleisner A
    Ann Surg Oncol; 2022 Feb; 29(2):806-815. PubMed ID: 34537899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. International Center-Level Variation in Utilization of Completion Lymph Node Dissection and Adjuvant Systemic Therapy for Sentinel Lymph Node-Positive Melanoma at Major Referral Centers.
    Broman KK; Hughes TM; Bredbeck BC; Sun J; Kirichenko D; Carr MJ; Sharma A; Bartlett EK; Nijhuis AAG; Thompson JF; Hieken TJ; Kottschade L; Downs J; Gyorki DE; Stahlie E; van Akkooi A; Ollila DW; O'shea K; Song Y; Karakousis G; Moncrieff M; Nobes J; Vetto J; Han D; Hotz M; Farma JM; Deneve JL; Fleming MD; Perez M; Baecher K; Lowe M; Bagge RO; Mattsson J; Lee AY; Berman RS; Chai H; Kroon HM; Teras J; Teras RM; Farrow NE; Beasley GM; Hui JYC; Been L; Kruijff S; Sinco B; Sarnaik AA; Sondak VK; Zager JS; Dossett LA;
    Ann Surg; 2023 May; 277(5):e1106-e1115. PubMed ID: 35129464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morbidity and recurrence after completion lymph node dissection following sentinel lymph node biopsy in cutaneous malignant melanoma.
    Guggenheim MM; Hug U; Jung FJ; Rousson V; Aust MC; Calcagni M; Künzi W; Giovanoli P
    Ann Surg; 2008 Apr; 247(4):687-93. PubMed ID: 18362633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Research progress of sentinel lymph node biopsy and regional dissection in melanoma].
    Liu WF; Yang FJ; Niu XH
    Zhonghua Zhong Liu Za Zhi; 2019 Jul; 41(7):481-485. PubMed ID: 31357833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.
    Eggermont AM
    Recent Results Cancer Res; 2000; 157():178-89. PubMed ID: 10857171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial].
    Sávolt A; Musonda P; Mátrai Z; Polgár C; Rényi-Vámos F; Rubovszky G; Kovács E; Sinkovics I; Udvarhelyi N; Török K; Kásler M; Péley G
    Orv Hetil; 2013 Dec; 154(49):1934-42. PubMed ID: 24292111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma.
    Wagner JD; Ranieri J; Evdokimow DZ; Logan T; Chuang TY; Johnson CS; Jung SH; Wenck S; Coleman JJ
    Plast Reconstr Surg; 2003 Aug; 112(2):486-97. PubMed ID: 12900606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.